Inspire Medical Systems, Inc. Earnings Recaps
Inspire Medical’s shares fell 7.9% despite Q3 revenue and adjusted operating income coming in slightly ahead of management’s expectations. The call’s emphasis on helping patient flow and building momentum for 2027, alongside the need to invest through 2026, suggests that near-term growth remains a concern; the transcript does not provide a specific guidance cut.
Key takeaways
- Revenue increased 3% sequentially. Management also cited strong operating cash flow, but gave no revenue or earnings figures in the provided transcript.
- Inspire is investing in patient access and conversion, with additional field roles planned in approximately 40 high-potential markets and further investment expected in Q4.
- Management said the final 2027 OPPS reimbursement rule was still pending, expected later that week; the July proposal showed a significant increase.
- A new Category I CPT code for single-lead hypoglossal nerve stimulation is scheduled to take effect January 1, 2028. Reimbursement valuation remains under review.
- Inspire V adoption was described as strong. Management cited improved inspiratory overlap in early assessments, while the transcript provides no specific clinical outcome figures.
Inspire Medical Systems shares surged 27.7% following Q2 results as the company raised full-year guidance on revenue, adjusted operating margin, and adjusted EPS, driven by improved coding clarity and reimbursement initiatives that buoyed investor confidence.
Key takeaways
- Q2 adjusted operating income and positive cash flow came in ahead of expectations due to disciplined cost management.
- Company highlighted improved prior authorization submissions and clearer coding guidance for the Inspire V system, reducing payer confusion.
- CMS has proposed 12% and 15% increases in 2027 hospital outpatient and ASC reimbursement rates respectively for Inspire V procedures.
- Despite a 4% proposed decrease in physician reimbursement, management is advancing efforts to secure a new Category 1 CPT code for a single lead Inspire system, with approval expected in September.
- The new Project Horizon strategic growth plan aims to accelerate revenue growth by investing $30 million annually to optimize patient flow, organizational structure, and supply chain efficiencies.
Shares dropped 14.9% following the quarter as investors reacted negatively to a revised full-year revenue outlook amid ongoing coding and reimbursement challenges, compounded by headwinds from the new WISER prior authorization program.
Key takeaways
- Revenue growth and adjusted operating income improved versus prior year, but underlying operational challenges persist.
- Significant coding and reimbursement uncertainties remain, particularly for the Inspire V system, with only partial short-term solutions in place.
- Medicare’s new C-code for Inspire V provides some clarity, but broader commercial payer coding remains inconsistent, requiring manual reviews and prior authorizations.
- The WISER program introduced prior authorization delays in six states, adversely impacting first-quarter revenue and creating ongoing headwinds.
- Management is increasing customer support and education to improve prior authorization success and expects coding and reimbursement trends to stabilize later in the year.
Inspire Medical Systems delivered robust third-quarter results, with revenue rising 10% year-over-year to $224.5 million, supported by strong patient adoption and favorable reimbursement developments.
Key takeaways
- Operating income reached $9.6 million, with earnings per share guidance upgraded to $0.90–$1.00, reflecting improved cost discipline and revenue growth.
- Physician training for the Inspire V system is over 98% complete, and contracting is over 90% finalized, positioning the company for a successful product launch.
- Recent clinical studies highlighted Inspire’s effectiveness in reducing long-term cardiovascular risks in OSA patients, reinforcing the company's commitment to innovation and patient outcomes.